Skip to main content

Table 3 Patients with poorly controlled hypertension, dyslipidemia, or diabetes mellitus, who had subsequent therapy modifications within a 6-months or 12 months-period

From: Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study

  Patients with poorly controlled hypertension Patients with poorly controlled dyslipidemia Patients with poorly controlled diabetes mellitus
  6 Months 12 Months 6 Months 12 Months 6 Months 12 Months
  n % n % n % n % n % n %
Appropriate clinical action 211 54.0 240 61.4 67 29.0 87 37.7 46 78.0 50 84.7
Any therapy modification 193 49.4 238 60.9 55 23.8 77 33.3 44 74.6 50 84.7
Increase class 121 30.9 153 39.1 43 18.6 64 27.7 26 44.1 30 50.8
Increase dose 103 26.3 135 34.5 15 6.5 23 10.0 31 52.5 36 61.0
Switch class 30 7.7 49 12.5 0 0.0 2 0.9 6 10.2 10 16.9
Several modifications 55 14.1 88 22.5 3 1.3 11 4.8 19 32.2 26 44.1
Return to control WO modification 18 4.6 2 0.5 12 5.2 10 4.3 2 3.4 0 0.0
Inappropriate clinical action 180 46.0 151 38.6 164 71.0 144 62.3 13 22.0 9 15.3
No modification, return to near control 25 6.4 9 2.3 38 16.5 27 11.7 1 1.7 3 5.1
No modification, no return 120 30.7 134 34.3 40 17.3 40 17.3 7 11.9 2 3.4
No measurement, no modification 35 9.0 8 2.0 86 37.2 77 33.3 5 8.5 4 6.8
  1. LDL = low-density lipoprotein. A switch to different drug class was counted when a new class of medication for the condition was added, but the total number of drug classes remained the same. Categories of control with levels of control, near and poor control for hypertension, dyslipidemia and diabetes mellitus are based on N. Rodondi et al. [5]. This category includes patients without visit or measurements.